Mineralys Therapeutics, Inc. MLYS 深 沪
已收盘 10-17 16:00:00 美东时间
43.56
+0.590
+1.37%
华盛通- 最 高43.895
- 今 开42.74
- 成交量 94.49万股
- 最 低 41.738
- 昨 收 42.97
- 总市值 28.88亿
- 52周最高 44.80
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 8.241
- 委 比 2.43%
- 总股本 6629.52万
- 历史最高 44.80
- 量 比 0.59
- 振 幅 5.02%
- 历史最低 5.85
- 每 手 1
- 风险率 8.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
Mineralys Therapeutics Inc.宣布完成了其Phase 2 EXPLORE-OSA试验的参与者入组，该试验评估其药物lorundrostat对伴有中重度阻塞性睡眠呼吸暂停（OSA）和高血压患者的疗效。公司预计将在2026年第一季度公布试验的顶端线结果。OSA与高血压密切相关，且现有治疗方法有限，存在显著未满足的医疗需求。Lorundrostat是一种高选择性醛固酮合成酶抑制剂，旨在通过减少醛固酮的产生来控制血压。此试验的成功可能为更多患者提供有效治疗选择。
09-30 12:00
Goldman's 48 potential M&A candidates
Deal activity will rise by 15% in 2026, according to Goldman Sachs. Strategist David Kostin says M&A activity will increase next year "alongside accelerating US economic growth, improving CEO confiden...
09-29 03:14
SA Asks: Which biotechs could be acquired by year's end?
The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked Seeking Alpha analysts Stephen Ayers ...
09-14 04:18
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
美股大行评级 | 潜在涨幅37.57%！Mama's Creations获Roth Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Roth Capital：维持Mama's Creations"买入"评级，目标价从10美元升至13美元；高盛：维持Mineralys Therapeutics"买入"评级，目标价从32美元升至52美元
09-10 09:47
美股周涨跌榜 | 医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%
医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%，肺纤维化治疗取得重大突破；Lululemon周跌17%，此前下调年度利润及销售额预期>>
09-06 10:02
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
Mineralys Therapeutics announced positive subgroup analysis from the Phase 3 Launch-HTN trial of lorundrostat, demonstrating significant blood pressure reduction across diverse high-risk populations, including Black/African American adults, older adults, women, and those with obesity, with a favorable safety profile. The trial, the largest in uncontrolled or resistant hypertension, enrolled 1,083 participants on 2-5 antihypertensives, achieving r...
09-05 13:00
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Mineralys Therapeutics completed an underwritten public offering of 11,274,509 shares, including an additional 1,470,588 shares, at $25.50 per share, raising approximately $287.5 million. The proceeds will fund clinical development of lorundrostat, manufacturing, and pre-commercialization activities. Major underwriters included BofA Securities, Evercore ISI, Goldman Sachs, Stifel, and Wells Fargo Securities. The offering was conducted under SEC-r...
09-04 20:01
Mineralys完成2.5亿美元股票发行定价
美股周三早盘，生物技术公司Mineralys Therapeutics（MLYS）股价下跌2.3%，此前该公司将其规模扩大后的2.5亿美元股票发行价格定为每...
09-03 22:38
